Antiproliferative effects of imatinib mesylate on ZR‑75‑1 and MDA‑MB‑231 cell lines via PDGFR‑β, PDGF‑BB, c‑Kit and SCF expression Corrigendum in /10.3892/ijmm.2019.4119

Kadivar,Ali; Ibrahim Noordin,Mohamed; Aditya,Arya; Kamalidehghan,Behnam; Davoudi,Ehsan   Taghizadeh; Sedghi,Reihaneh; Akbari Javar,Hamid

doi:10.3892/ijmm.2018.3590

Antiproliferative effects of imatinib mesylate on ZR‑75‑1 and MDA‑MB‑231 cell lines via PDGFR‑β, PDGF‑BB, c‑Kit and SCF expression

Corrigendum in 10.3892/ijmm.2019.4119

Authors:
- Ali Kadivar
- Mohamed Ibrahim Noordin
- Arya Aditya
- Behnam Kamalidehghan
- Ehsan Taghizadeh Davoudi
- Reihaneh Sedghi
- Hamid Akbari Javar
View Affiliations

Affiliations: Department of Pharmacy, Faculty of Medicine, University of Malaya, 50603 Kuala Lumpur, Malaysia, Department of Pharmacology and Therapeutics, School of Medicine, Faculty of Health and Medical Sciences, Taylor’s University, 47500 Subang Jaya, Malaysia, Faculty of Medicine, Shiraz University of Medical Sciences (SUMS), Shiraz 71348‑14336, Iran, Department of Pharmaceutics, Faculty of Pharmacy, Tehran University of Medical Sciences (TUMS), 14176‑13151 Tehran, Iran
Published online on: March 27, 2018 https://doi.org/10.3892/ijmm.2018.3590
Pages: 414-424

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Imatinib mesylate is an anti‑neoplastic targeted chemotherapeutic agent, which can inhibit tyrosine kinase receptors, including BCR‑ABL, platelet‑derived growth factor receptors (PDGFRs) and c‑Kit. Cellular processes, including differentiation, proliferation and survival are regulated by these receptors. The present study aimed to evaluate the antiproliferative effects of imatinib mesylate, and its effects on apoptotic induction and cell cycle arrest in breast cancer cell lines. In addition, the study aimed to determine whether the effects of this drug were associated with the mRNA and protein expression levels of PDGFR‑β, c‑Kit, and their corresponding ligands PDGF‑BB and stem cell factor (SCF), which may potentially modulate cell survival and proliferation. To assess the antiproliferative effects of imatinib mesylate, an MTS assay was conducted following treatment of cells with 2‑10 µM imatinib mesylate for 96, 120 and 144 h; accordingly the half maximal inhibitory concentration of imatinib mesylate was calculated for each cell line. In addition, the proapoptotic effects and cytostatic activity of imatinib mesylate were investigated. To evaluate the expression of imatinib‑targeted genes, PDGFR‑β, c‑Kit, PDGF‑BB and SCF, under imatinib mesylate treatment, mRNA expression was detected using semi‑quantitative polymerase chain reaction and protein expression was detected by western blot analysis in ZR‑75‑1 and MDA‑MB‑231 breast carcinoma cell lines. Treatment with imatinib mesylate suppressed cell proliferation, which was accompanied by apoptotic induction and cell cycle arrest in the investigated cell lines. In addition, PDGFR‑β, PDGF‑BB, c‑Kit and SCF were expressed in both breast carcinoma cell lines; PDGFR‑β and c‑Kit, as imatinib targets, were downregulated in response to imatinib mesylate treatment. The present results revealed that at least two potential targets of imatinib mesylate were expressed in the two breast carcinoma cell lines studied. In conclusion, the antiproliferative, cytostatic and proapoptotic effects of imatinib mesylate may be the result of a reduction in the expression of c‑Kit and PDGFR tyrosine kinase receptors, thus resulting in suppression of the corresponding ligand PDGF‑BB. Therefore, imatinib mesylate may be considered a promising target therapy for the future treatment of breast cancer.

View Figures

View References

1	Stewart B and Wild CP: World Cancer Report 2014. WORLD. 2015.
2	Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M, Thürlimann B and Senn HJ; Panel Members: Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol. 26:1533–1546. 2015. View Article : Google Scholar : PubMed/NCBI
3	Lopez L, Carvajal C, Gallardo M and Russo N: Evolution in breast cancer suspicion and extent of surgery at a radio-oncology center. Rev Chil Cir. 66:241–244. 2014.
4	Ross JS, Fletcher JA, Bloom KJ, Linette GP, Stec J, Symmans WF, Pusztai L and Hortobagyi GN: Targeted therapy in breast cancer: The HER-2/neu gene and protein. Mol Cell Proteomics. 3:379–398. 2004. View Article : Google Scholar : PubMed/NCBI
5	Ellis MJ, Coop A, Singh B, Mauriac L, Llombert-Cussac A, Jänicke F, Miller WR, Evans DB, Dugan M, Brady C, et al: Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: Evidence from a phase III randomized trial. J Clin Oncol. 19:3808–3816. 2001. View Article : Google Scholar : PubMed/NCBI
6	Jordan VC: Tamoxifen (ICI46,474) as a targeted therapy to treat and prevent breast cancer. Br J Pharmacol. 147(Suppl 1): S269–S276. 2006. View Article : Google Scholar : PubMed/NCBI
7	Gschwind A, Fischer OM and Ullrich A: The discovery of receptor tyrosine kinases: Targets for cancer therapy. Nat Rev Cancer. 4:361–370. 2004. View Article : Google Scholar : PubMed/NCBI
8	LaVallee TM, Alvarado D, Garton AJ, Trombetta ES, Gedrich R and McMahon G: Emerging receptor tyrosine kinase drug targets: Implications for antibody-based therapies for oncology and immunologic disorders. Crit Rev Oncog. 20:485–508. 2015. View Article : Google Scholar : PubMed/NCBI
9	Kadivar A, Kamalidehghan B, Javar HA, Davoudi ET, Zaharuddin ND, Sabeti B, Chung LY and Noordin MI: Formulation and in vitro, in vivo evaluation of effervescent floating sustained-release imatinib mesylate tablet. PLoS One. 10:e01268742015. View Article : Google Scholar : PubMed/NCBI
10	Manley PW, Cowan-Jacob SW, Buchdunger E, Fabbro D, Fendrich G, Furet P, Meyer T and Zimmermann J: Imatinib: A selective tyrosine kinase inhibitor. Eur J Cancer. 38(Suppl 5): S19–S27. 2002. View Article : Google Scholar
11	Radford IR: Imatinib. Novartis Curr Opin Investig Drugs. 3:492–499. 2002.
12	Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ and Lydon NB: Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther. 295:139–145. 2000.PubMed/NCBI
13	Malavaki CJ, Roussidis AE, Gialeli C, Kletsas D, Tsegenidis T, Theocharis AD, Tzanakakis GN and Karamanos NK: Imatinib as a key inhibitor of the platelet-derived growth factor receptor mediated expression of cell surface heparan sulfate proteoglycans and functional properties of breast cancer cells. FEBS J. 280:2477–2489. 2013. View Article : Google Scholar : PubMed/NCBI
14	Dong Y, Han Q, Zou Y, Deng Z, Lu X, Wang X, Zhang W, Jin H, Su J, Jiang T, et al: Long-term exposure to imatinib reduced cancer stem cell ability through induction of cell differentiation via activation of MAPK signaling in glioblastoma cells. Mol Cell Biochem. 370:89–102. 2012. View Article : Google Scholar : PubMed/NCBI
15	Verweij J, van Oosterom A, Blay J-Y, Judson I, Rodenhuis S, van der Graaf W, Radford J, Le Cesne A, Hogendoorn PC, di Paola ED, et al: Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur J Cancer. 39:2006–2011. 2003. View Article : Google Scholar : PubMed/NCBI
16	Paschka P, Marcucci G, Ruppert AS, Mrózek K, Chen H, Kittles RA, Vukosavljevic T, Perrotti D, Vardiman JW, Carroll AJ, et al Cancer and Leukemia Group B: Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): A Cancer and Leukemia Group B Study. J Clin Oncol. 24:3904–3911. 2006. View Article : Google Scholar : PubMed/NCBI
17	Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA and Zigler AJ: Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood. 96:925–932. 2000.PubMed/NCBI
18	Weigel MT, Meinhold-Heerlein I, Bauerschlag DO, Schem C, Bauer M, Jonat W, Maass N and Mundhenke C: Combination of imatinib and vinorelbine enhances cell growth inhibition in breast cancer cells via PDGFR β signalling. Cancer Lett. 273:70–79. 2009. View Article : Google Scholar
19	Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, et al: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 347:472–480. 2002. View Article : Google Scholar : PubMed/NCBI
20	Bond M, Bernstein ML, Pappo A, Schultz KR, Krailo M, Blaney SM and Adamson PC: A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: A Children's Oncology Group study. Pediatr Blood Cancer. 50:254–258. 2008. View Article : Google Scholar
21	Matei D, Chang DD and Jeng M-H: Imatinib mesylate (Gleevec) inhibits ovarian cancer cell growth through a mechanism dependent on platelet-derived growth factor receptor α and Akt inactivation. Clin Cancer Res. 10:681–690. 2004. View Article : Google Scholar
22	Gross DJ, Munter G, Bitan M, Siegal T, Gabizon A, Weitzen R, Merimsky O, Ackerstein A, Salmon A, Sella A, et al Israel Glivec in Solid Tumors Study Group: The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R. Endocr Relat Cancer. 13:535–540. 2006. View Article : Google Scholar : PubMed/NCBI
23	de Jong JS, van Diest PJ, van der Valk P and Baak JP: Expression of growth factors, growth inhibiting factors, and their receptors in invasive breast cancer. I: An inventory in search of autocrine and paracrine loops. J Pathol. 184:44–52. 1998. View Article : Google Scholar : PubMed/NCBI
24	Lopes LF and Bacchi CE: Imatinib treatment for gastrointestinal stromal tumour (GIST). J Cell Mol Med. 14:42–50. 2010. View Article : Google Scholar
25	Kim KB, Eton O, Davis DW, Frazier ML, McConkey DJ, Diwan AH, Papadopoulos NE, Bedikian AY, Camacho LH, Ross MI, et al: Phase II trial of imatinib mesylate in patients with metastatic melanoma. Br J Cancer. 99:734–740. 2008. View Article : Google Scholar : PubMed/NCBI
26	Rutkowski P, Van Glabbeke M, Rankin CJ, Ruka W, Rubin BP, Debiec-Rychter M, Lazar A, Gelderblom H, Sciot R, Lopez-Terrada D, et al European Organisation for Research and Treatment of Cancer Soft Tissue/Bone Sarcoma Group; Southwest Oncology Group: Imatinib mesylate in advanced dermatofibrosarcoma protuberans: Pooled analysis of two phase II clinical trials. J Clin Oncol. 28:1772–1779. 2010. View Article : Google Scholar : PubMed/NCBI
27	Mahata S, Maru S, Shukla S, Pandey A, Mugesh G, Das BC and Bharti AC: Anticancer property of Bryophyllum pinnata (Lam.) Oken leaf on human cervical cancer cells. BMC Complement Altern Med. 12:152012. View Article : Google Scholar
28	Pfaffl MW, Horgan GW and Dempfle L: Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res. 30:e362002. View Article : Google Scholar : PubMed/NCBI
29	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar
30	Hu S, Franke RM, Filipski KK, Hu C, Orwick SJ, de Bruijn EA, Burger H, Baker SD and Sparreboom A: Interaction of imatinib with human organic ion carriers. Clin Cancer Res. 14:3141–3148. 2008. View Article : Google Scholar : PubMed/NCBI
31	Beppu K, Jaboine J, Merchant MS, Mackall CL and Thiele CJ: Effect of imatinib mesylate on neuroblastoma tumorigenesis and vascular endothelial growth factor expression. J Natl Cancer Inst. 96:46–55. 2004. View Article : Google Scholar : PubMed/NCBI
32	Jin S, Shen JN, Wang J, Huang G and Zhou JG: Oridonin induced apoptosis through Akt and MAPKs signaling pathways in human osteosarcoma cells. Cancer Biol Ther. 6:261–268. 2007. View Article : Google Scholar : PubMed/NCBI
33	Uziel O, Fenig E, Nordenberg J, Beery E, Reshef H, Sandbank J, Birenbaum M, Bakhanashvili M, Yerushalmi R, Luria D, et al: Imatinib mesylate (Gleevec) downregulates telomerase activity and inhibits proliferation in telomerase-expressing cell lines. Br J Cancer. 92:1881–1891. 2005. View Article : Google Scholar : PubMed/NCBI
34	Peng B, Lloyd P and Schran H: Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 44:879–894. 2005. View Article : Google Scholar : PubMed/NCBI
35	Heldin CH: Targeting the PDGF signaling pathway in tumor treatment. Cell Commun Signal. 11:972013. View Article : Google Scholar : PubMed/NCBI
36	Tsimberidou AM, Kurzrock R and Anderson KC: The role of angiogenesis in cancer. Target Ther Transl Cancer Res. 5:642015.
37	Kofler S, Nickel T and Weis M: Role of cytokines in cardiovascular diseases: A focus on endothelial responses to inflammation. Clin Sci (Lond). 108:205–213. 2005. View Article : Google Scholar
38	Vrekoussis T, Stathopoulos EN, Kafousi M, Navrozoglou I and Zoras O: Expression of endothelial PDGF receptors α and β in breast cancer: Up-regulation of endothelial PDGF receptor β. Oncol Rep. 17:1115–1119. 2007.PubMed/NCBI
39	Nazarenko I, Hede S-M, He X, Hedrén A, Thompson J, Lindström MS and Nistér M: PDGF and PDGF receptors in glioma. Ups J Med Sci. 117:99–112. 2012. View Article : Google Scholar : PubMed/NCBI
40	Wilczynski SP, Chen Y-Y, Chen W, Howell SB, Shively JE and Alberts DS: Expression and mutational analysis of tyrosine kinase receptors c-kit, PDGFRalpha, and PDGFRbeta in ovarian cancers. Hum Pathol. 36:242–249. 2005. View Article : Google Scholar : PubMed/NCBI
41	Jechlinger M, Sommer A, Moriggl R, Seither P, Kraut N, Capodiecci P, Donovan M, Cordon-Cardo C, Beug H and Grünert S: Autocrine PDGFR signaling promotes mammary cancer metastasis. J Clin Invest. 116:1561–1570. 2006. View Article : Google Scholar : PubMed/NCBI
42	Geng L, Shinohara ET, Kim D, Tan J, Osusky K, Shyr Y and Hallahan DE: STI571 (Gleevec) improves tumor growth delay and survival in irradiated mouse models of glioblastoma. Int J Radiat Oncol Biol Phys. 64:263–271. 2006. View Article : Google Scholar
43	Board R and Jayson GC: Platelet-derived growth factor receptor (PDGFR): A target for anticancer therapeutics. Drug Resist Updat. 8:75–83. 2005. View Article : Google Scholar : PubMed/NCBI